What question did this study set out to answer?

To evaluate longitudinal trends in risk factor control and therapeutic patterns among patients diagnosed with both non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020.

February 23, 2023Alimentary Pharmacology & TherapeuticsOpen Access

Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

View Full Paper

Ask AI

Bookmark

Authors

XZXinrong ZhangSun Yat-sen University TYTerry Cheuk‐Fung YipChinese University of Hong Kong YTYee‐Kit TseChinese University of Hong Kong

Discussion

Member takes

Implication

Cohort study shows improved glucose and lipid control but stagnant blood pressure in fatty liver disease and diabetes, highlighting persistent cardiovascular care gaps.

Key Points

To evaluate longitudinal trends in risk factor control and therapeutic patterns among patients diagnosed with both non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020.
Conducted a territory-wide cohort study involving 16,084 adult patients with NAFLD and T2D diagnosed between 1 January 2000 and 31 July 2021 in Hong Kong (mean age, 54.8 ± 12.0 years; 44.3% male).
Identified type 2 diabetes via antidiabetic medication prescriptions, laboratory test thresholds, and formal clinical diagnostic coding.
Between 2000–2005 and 2016–2020, target achievement increased from 44.5% (95% CI, 42.9–46.1) to 64.8% (95% CI, 64.1–65.5) for HbA1c and from 23.3% (95% CI, 21.9–24.7) to 54.3% (95% CI, 53.5–55.1) for LDL-C.
Blood pressure control (<140/90 mm Hg) remained unchanged over time at 53.1% to 57.2%, accompanied by a lack of uptake in combination antihypertensive therapies.
Patients with cirrhosis had lower rates of blood pressure and LDL-C control with underuse of metformin and statins, though their individualized HbA1c target achievement exceeded that of non-cirrhotic patients.

Cite This Study

Zhang et al. (2023) studied this question.

synapsesocial.com/papers/6aa3f35d85bea8c196b142f2 https://doi.org/10.1111/apt.17428

View Full Paper

Ask AI

Bookmark

Implication

Cohort study shows improved glucose and lipid control but stagnant blood pressure in fatty liver disease and diabetes, highlighting persistent cardiovascular care gaps.

Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

Discussion

Member takes

Implication

Key Points

Cite This Study

Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider